Literature DB >> 16949733

Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing.

Jan Schindehütte1, Claudia Trenkwalder.   

Abstract

"Atypical anti-psychotics" are substances of choice in treating drug-induced psychosis (DP) in Parkinson's disease (PD). We report on four patients with DP who received treatment with ziprasidone after previously applied clozapine and quetiapine had failed. Three patients showed a significant improvement of DP, without deterioration of motor function. In one case, ziprasidone considerably increased decline in off-periods. Two patients developed pathological laughing as a possible side-effect of ziprasidone. Ziprasidone may serve as an additional "atypical anti-psychotic" for the treatment of DP in PD but can also induce deterioration of motor function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16949733     DOI: 10.1016/j.clineuro.2006.07.003

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  16 in total

Review 1.  An update expert opinion on management and research strategies in Parkinson's disease psychosis.

Authors:  Jennifer G Goldman; Christina L Vaughan; Christopher G Goetz
Journal:  Expert Opin Pharmacother       Date:  2011-06-02       Impact factor: 3.889

2.  Chemogenomics knowledgebase and systems pharmacology for hallucinogen target identification-Salvinorin A as a case study.

Authors:  Xiaomeng Xu; Shifan Ma; Zhiwei Feng; Guanxing Hu; Lirong Wang; Xiang-Qun Xie
Journal:  J Mol Graph Model       Date:  2016-08-08       Impact factor: 2.518

Review 3.  [Parkinson's disease and psychoses].

Authors:  Jacopo Vittoriano Bizzarri; Giancarlo Giupponi; Ignazio Maniscalco; Patrizia Schroffenegger; Andreas Conca; Hans Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2015-01-14

Review 4.  Neuropsychiatric Issues in Parkinson's Disease.

Authors:  Jeffrey W Cooney; Mark Stacy
Journal:  Curr Neurol Neurosci Rep       Date:  2016-05       Impact factor: 5.081

5.  Low FAB score as a predictor of future falling in patients with Parkinson's disease: a 2.5-year prospective study.

Authors:  Hiroshi Kataoka; Satoshi Ueno
Journal:  J Neurol       Date:  2015-06-17       Impact factor: 4.849

Review 6.  Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Authors:  Barbara Connolly; Susan H Fox
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

7.  Treatment of Parkinson's disease psychosis.

Authors:  Kevin J Black
Journal:  Med Int Rev       Date:  2018-02-03

Review 8.  Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.

Authors:  Shyam C Panchal; William G Ondo
Journal:  Curr Psychiatry Rep       Date:  2018-01-27       Impact factor: 5.285

Review 9.  Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.

Authors:  Anna Chang; Susan H Fox
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

10.  Predictable Risk Factors for the Feeling of Presence in Patients with Parkinson's Disease.

Authors:  Hiroshi Kataoka; Satoshi Ueno
Journal:  Mov Disord Clin Pract       Date:  2015-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.